C W Sies

Summary

Country: New Zealand

Publications

  1. ncbi Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine
    Christiaan Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    N Z Med J 118:U1324. 2005
  2. ncbi Clinical indications for the investigation of porphyria: case examples and evolving laboratory approaches to its diagnosis in New Zealand
    Christiaan Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    N Z Med J 118:U1658. 2005
  3. ncbi Urinary VMA, dopamine and the likelihood of neuroblastoma: a preferred way of reporting laboratory results?
    C W Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, PO Box 151, Christchurch, New Zealand
    Ann Clin Biochem 43:300-5. 2006
  4. ncbi Quartz renal calculi: were we being led up the garden path?
    C W Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Ann Clin Biochem 44:312-4. 2007
  5. ncbi Uncertainty of sweat chloride testing: does the right hand know what the left hand is doing?
    R J MacKay
    Biochemistry Unit, Canterbury Health Laboratories, PO Box 151, Christchurch 8011, New Zealand
    Ann Clin Biochem 45:535-8. 2008
  6. ncbi Dual porphyria with mutations in both the UROD and HMBS genes
    James R Harraway
    Molecular Pathology, Canterbury Health Laboratories, P O Box 151, Christchurch, New Zealand
    Ann Clin Biochem 43:80-2. 2006

Collaborators

  • Richard Gearry
  • R J MacKay
  • James R Harraway
  • S Woods
  • P M George
  • C M Florkowski
  • Peter M George
  • Christopher M Florkowski

Detail Information

Publications6

  1. ncbi Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine
    Christiaan Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    N Z Med J 118:U1324. 2005
    ....
  2. ncbi Clinical indications for the investigation of porphyria: case examples and evolving laboratory approaches to its diagnosis in New Zealand
    Christiaan Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    N Z Med J 118:U1658. 2005
    ..Accurate screening and diagnosis of porphyria is important, as an acute porphyric attack is life-threatening and preventable. Retrospective diagnosis may be difficult...
  3. ncbi Urinary VMA, dopamine and the likelihood of neuroblastoma: a preferred way of reporting laboratory results?
    C W Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, PO Box 151, Christchurch, New Zealand
    Ann Clin Biochem 43:300-5. 2006
    ..We therefore evaluated the utility of positive likelihood ratios (LR+) based on data from patients in whom the diagnosis was suspected...
  4. ncbi Quartz renal calculi: were we being led up the garden path?
    C W Sies
    Clinical Biochemistry Unit, Canterbury Health Laboratories, Christchurch, New Zealand
    Ann Clin Biochem 44:312-4. 2007
    ..This case highlights the usefulness of XRD in the differentiation of authentic from possibly factitious renal calculi...
  5. ncbi Uncertainty of sweat chloride testing: does the right hand know what the left hand is doing?
    R J MacKay
    Biochemistry Unit, Canterbury Health Laboratories, PO Box 151, Christchurch 8011, New Zealand
    Ann Clin Biochem 45:535-8. 2008
    ..This has important implications for reporting...
  6. ncbi Dual porphyria with mutations in both the UROD and HMBS genes
    James R Harraway
    Molecular Pathology, Canterbury Health Laboratories, P O Box 151, Christchurch, New Zealand
    Ann Clin Biochem 43:80-2. 2006
    ..Sequencing of the hydroxymethylbilane synthase and uroporphyrinogen decarboxylase genes confirmed the relatively rare diagnosis of dual porphyria, and revealed a novel uroporphyrinogen decarboxylase mutation...